Genomic profiling of mycobacterium tuberculosis strains, Myanmar

Autor: Patrick J. Biggs, Wint Wint Nyunt, Yang Fong, Htin Lin Aung, Philip C. Hill, Tsin W. Yeo, Peter J. Lockhart, Gregory M. Cook, Richard C. Winkworth, Si Thu Aung
Přispěvatelé: Lee Kong Chian School of Medicine (LKCMedicine)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Microbiology (medical)
Tuberculosis
Epidemiology
Population
Infectious and parasitic diseases
RC109-216
Myanmar
Microbial Sensitivity Tests
Genomic Profiling of Mycobacterium tuberculosis Strains
Myanmar
Mycobacterium tuberculosis
strains
chemistry.chemical_compound
respiratory infections
Antibiotic resistance
Drug Resistance
Bacterial
Tuberculosis
Multidrug-Resistant
Medicine
expanded drug resistance testing
Humans
Medicine [Science]
antimicrobial resistance
education
bacteria
education.field_of_study
GeneXpert MTB/RIF
biology
business.industry
Research
Genomics
biology.organism_classification
medicine.disease
Virology
tuberculosis and other mycobacteria
Multiple drug resistance
Infectious Diseases
chemistry
tuberculosis
Susceptibility
Pretomanid
Drug-Resistant Tuberculosis
Bedaquiline
genomic profiling
Rifampin
business
new oral regimens
Zdroj: Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 27, Iss 11, Pp 2847-2855 (2021)
Popis: Multidrug resistance is a major threat to global elimination of tuberculosis (TB). We performed phenotypic drug-susceptibility testing and whole-genome sequencing for 309 isolates from 342 consecutive patients who were given a diagnosis of TB in Yangon, Myanmar, during July 2016. June 2018. We identified isolates by using the GeneXpert platform to evaluate drug-resistance profiles. A total of 191 (62%) of 309 isolates had rifampin resistance; 168 (88%) of these rifampin-resistant isolates were not genomically related, indicating the repeated emergence of resistance in the population, rather than extensive local transmission. We did not detect resistance mutations to new oral drugs, including bedaquiline and pretomanid. The current GeneXpert MTB/RIF system needs to be modified by using the newly launched Xpert MTB/XDR cartridge or line-probe assay. Introducing new oral drugs to replace those currently used in treatment regimens for multidrug-resistant TB will also be useful for treating TB in Myanmar. Published version This study was supported by the New Zealand Health Research Council through the e-ASIA funding scheme. H.L.A. is a Health Research Council Sir Charles Hercus Health Research Fellow.
Databáze: OpenAIRE
Externí odkaz: